Trump won a second term. What does it mean for biopharma?

Over his first term, Donald Trump advocated for lower drug prices and pharmacy benefit manager reform.

Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry. Bausch + Lomb's CEO is 'optimistic,' while Curie.Bio CEO ...

The president-elect has said he'll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change at the FTC could ...

With Donald Trump securing a second presidential term, what issues should be top of mind for the pharmaceutical sector in the US?

A panel at the Financial Times' 2024 Global Pharma and Biotech Summit in London analyzed what the re-election of Trump could mean to the ...

Innovative drug development "the flavor of 2025" says Ali Pashazadeh, who discusses how the new administration will likely impact the ...

Many argue his presidency would be more positive for the industry overall, as Kamala Harris has her price-cutting sights squarely on Big Pharma.

On Wednesday, Republican candidate and former president Donald Trump was elected to the nation's highest office ...

Analyst reactions to Donald Trump's election victory were mixed Wednesday, with potential positives including an FTC that is likely to be ...

Biotech stocks jumped early Wednesday on hopes for more innovation and dealmaking after Election 2024 wrapped with a Donald Trump win.

Donald Trump has been elected the next president of the United States, which could have significant impacts on public health agencies, ...

Donald Trump has been elected 47th president of the US after the 5 November election having won more than the 270-seat threshold needed. Despite ...

Is less regulation by the Food and Drug Administration good for the biotech industry? Do vaccine makers like Pfizer have a target on their ...

As former President Donald Trump has clinched a second term with a victory, his health care priorities will differ somewhat from his first term, ...

“President Trump has promised to fire government scientists and to dismantle scientific agencies,” Jones says. “Without strong federal science, ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following months of ...

Barron's sizes up the likely impacts on the auto industry, energy, healthcare, industrials, regional banks, and technology.

Welcome back to Endpoints Weekly, your review of the week's top biopharma headlines. Want this in your inbox every Saturday morning?

The research community fears another Trump presidency will be worse than the first, but the chemical and biotech sectors are more ...

Harris aims to broaden some IRA provisions, including Medicare drug price negotiation, while Trump has adopted a more industry-friendly approach.